US.MRK · Merck & Co.

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.9244080145719487,
        "turnoverUsdM": 1096.94002374,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRK",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 113.7158,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.8,
      "take_profit_price": 127.8265,
      "target_multiplier": 1.9,
      "technical_strength": 1.58,
      "take_profit_percent": 5.8
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.848816029143897,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 48.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 45.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 122.8515,
    "ma50": 118.7166,
    "close": 120.78,
    "prevClose": 124.03,
    "avgVolume20": 11385882,
    "volumeRatio": 0.8,
    "changePercent": -2.62
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.06270370945211867,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.7912561464769492,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.1145233789913689,
      "volat_points": 0,
      "day_range_pct": 0.028895512502069953,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 48.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 15.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 53,
        "contribution": 15.9
      },
      {
        "raw": 1,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 10,
        "contribution": 1
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 45.5,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 15.9/30分",
      "情緒分析: 1/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.2,
      "資金流": 8.4,
      "市場環境": 8,
      "情緒分析": 1,
      "技術信號": 15.9,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.4,
          "marginPoints": 0.4,
          "turnoverUsdM": 1096.94002374,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRK",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 722.21300335,
                "ma50": 717.1976024399999,
                "name": "QQQ",
                "close": 719.67999,
                "points": 1.4
              },
              "spy": {
                "ma20": 744.8860105000001,
                "ma50": 742.6526037,
                "name": "SPY",
                "close": 751.83002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.9244080145719487,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 1,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 0,
              "sentimentScoreRaw": -0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140888430,
                "url": "https://finnhub.io/api/news?id=1878947d921411a7abc93a44daf05abd7d3b58271e42b8bb5bee329f2cdc7de1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.",
                "category": "company",
                "datetime": 1783955280,
                "headline": "FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer"
              },
              {
                "id": 140885871,
                "url": "https://finnhub.io/api/news?id=d281c232a9515f86e62357d878ab39deb1db50038740540ae1d56d022cad4a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...",
                "category": "company",
                "datetime": 1783948141,
                "headline": "Merck (MRK) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 140882586,
                "url": "https://finnhub.io/api/news?id=dacd024657c409a5c498848e3ea460855a813613f3eaad4a724b245c2221a6c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”",
                "category": "company",
                "datetime": 1783906437,
                "headline": "Nasdaq, S&P 500, Dow Futures Fall After Trump Directs Strikes ‘To Hold Iranian Forces Accountable’: NVDA, SLS, MRK, SKHYV, QS Stocks In Focus"
              },
              {
                "id": 140866942,
                "url": "https://finnhub.io/api/news?id=67631bafdf38a6e424b16afae605f0c6073132b0aa502c97ab9d6a2ef2e274bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783719905,
                "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140852182,
                "url": "https://finnhub.io/api/news?id=44e3f9e8461045391c4a83bc13f1bc62e5628bbd2f31024755d11d0d0b36d472",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783602006,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140846351,
                "url": "https://finnhub.io/api/news?id=f04de45506b1a90b3aaccb38d94091579d0f7a89baec41e482f1e15044ce0b0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has reached a new access agreement with the ADAP Crisis Task Force for its once daily HIV treatment IDVYNSO. This development gives investors fresh context for assessing the stock. See our latest analysis for Merck. Merck shares recently pulled back, with a 1-day share price return declining 2.23% to close at US$125.99. However, the 30-day share price return of 5.41% and 1-year total shareholder return of 55.54% point to momentum that remains broadly positive. If Merck’s recent...",
                "category": "company",
                "datetime": 1783548990,
                "headline": "Merck (MRK) Gets New HIV Access Deal As Its Valuation Narrative Stays In Focus"
              },
              {
                "id": 140845513,
                "url": "https://finnhub.io/api/news?id=549a6b89bc122af3450e9e6b2e9dafa75bced723502ae900d2404bf032669cec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast cancer and EU approval of KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. These approvals further entrench KEYTRUDA at the center of Merck’s cancer portfolio, broadening its use across hard-to-treat tumors while the company prepares for future loss of...",
                "category": "company",
                "datetime": 1783545346,
                "headline": "Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?"
              },
              {
                "id": 140840493,
                "url": "https://finnhub.io/api/news?id=684da8d2a4e5f5ee2cdba89a999ca639b2c146877af8d6e1d7fb5e72a1957ecb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.",
                "category": "company",
                "datetime": 1783513500,
                "headline": "MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?"
              }
            ],
            "raw_source": [
              {
                "id": 140901110,
                "url": "https://finnhub.io/api/news?id=a418695849289d29baabb02fccad0cc1323fa81f759a05f46d8ec554e1e50864",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1784056204,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140899749,
                "url": "https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.",
                "category": "company",
                "datetime": 1784046620,
                "headline": "This Healthcare Giant Still Checks Every Box for Long-Term Investors"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140900776,
                "url": "https://finnhub.io/api/news?id=472ffc9e1c34527f50c19adb2c3e53aab6255066151051c2bc57b056856451e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237287346/image_2237287346.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. Read more on SLS stock here.",
                "category": "company",
                "datetime": 1784041616,
                "headline": "SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up"
              },
              {
                "id": 140898076,
                "url": "https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.",
                "category": "company",
                "datetime": 1784039400,
                "headline": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"
              },
              {
                "id": 140898155,
                "url": "https://finnhub.io/api/news?id=6d4a33b47289f081e1decf603f5fe621103805f6f365d34500b2ac909e8a981c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.",
                "category": "company",
                "datetime": 1784037180,
                "headline": "Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?"
              },
              {
                "id": 140901522,
                "url": "https://finnhub.io/api/news?id=329dad206b26f18b6eb7034fd88d2e6909c2fbf288a547a9be1da75eeadf9637",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.",
                "category": "company",
                "datetime": 1784031042,
                "headline": "Earnings Preview: What To Expect From Merck & Co.'s Report"
              },
              {
                "id": 140889976,
                "url": "https://finnhub.io/api/news?id=853634e3215adae0307c8aa5ba126a884c266f5f82638bd677c0b4bb959be1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.",
                "category": "company",
                "datetime": 1783965635,
                "headline": "Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140888429,
                "url": "https://finnhub.io/api/news?id=13d6e4cd62b132435b52aa56bea0e9b4f7d918437b7a994997501f8c73faa29a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in GreeceFive-year agreement expected to contribute to revenue and cash-flow visibilityAs a prescription medicine, DIABIT-IS X is expected to be accessible to patients through Greece's national health insurance system, broadening its potential reachDIABIT-IS X is a generic alternative to Merck's Januvia®, which with Janumet® generated approximately $4.5 billion in combined global sales in 2022Po",
                "category": "company",
                "datetime": 1783962000,
                "headline": "Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece"
              },
              {
                "id": 140888430,
                "url": "https://finnhub.io/api/news?id=1878947d921411a7abc93a44daf05abd7d3b58271e42b8bb5bee329f2cdc7de1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.",
                "category": "company",
                "datetime": 1783955280,
                "headline": "FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140885871,
                "url": "https://finnhub.io/api/news?id=d281c232a9515f86e62357d878ab39deb1db50038740540ae1d56d022cad4a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...",
                "category": "company",
                "datetime": 1783948141,
                "headline": "Merck (MRK) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 140885872,
                "url": "https://finnhub.io/api/news?id=5278afd659ead48962f28b4c7f7426a6ba09e432440e8ca3612e6986e3a72192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026",
                "category": "company",
                "datetime": 1783944000,
                "headline": "Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004"
              },
              {
                "id": 140891097,
                "url": "https://finnhub.io/api/news?id=295cbdd3d345947d66f72242e33afe416d280d034c34dccdf44f3c75ccab4725",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "JP Morgan  analyst Chris Schott   maintains Merck &amp; Co (NYSE:MRK) with a Overweight and raises the price target from $135 to $140.",
                "category": "company",
                "datetime": 1783942998,
                "headline": "JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $140"
              },
              {
                "id": 140891098,
                "url": "https://finnhub.io/api/news?id=0c0f26bdc8ff5c2de071dcd765e06610e0c18b692931d25fb4618b4459ace900",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Merck &amp; Co (NYSE:MRK) with a Outperform and raises the price target from $135 to $142.",
                "category": "company",
                "datetime": 1783933123,
                "headline": "BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $142"
              },
              {
                "id": 140891099,
                "url": "https://finnhub.io/api/news?id=27bf2228e7a7e222be0d3ef3d3e7d164c856b60ef1554a9c7d45974efe7de02d",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Merck &amp; Co (NYSE:MRK) with a Buy and raises the price target from $140 to $145.",
                "category": "company",
                "datetime": 1783932000,
                "headline": "Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $145"
              },
              {
                "id": 140891100,
                "url": "https://finnhub.io/api/news?id=7deb3e439675b7d7a8298846a5863b276e19d71034129faf29754996c441be9d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Merck-Chooses-Switzerland.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck &amp; Co. shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.",
                "category": "company",
                "datetime": 1783930839,
                "headline": "Why Merck Stock Is in the Spotlight Today"
              },
              {
                "id": 140883027,
                "url": "https://finnhub.io/api/news?id=b44474c02fa172be73c1ab8b2c5b47a46b91d9a1e114148076ce91583e08715e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.",
                "category": "company",
                "datetime": 1783910910,
                "headline": "SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears"
              },
              {
                "id": 140882586,
                "url": "https://finnhub.io/api/news?id=dacd024657c409a5c498848e3ea460855a813613f3eaad4a724b245c2221a6c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”",
                "category": "company",
                "datetime": 1783906437,
                "headline": "Nasdaq, S&P 500, Dow Futures Fall After Trump Directs Strikes ‘To Hold Iranian Forces Accountable’: NVDA, SLS, MRK, SKHYV, QS Stocks In Focus"
              },
              {
                "id": 140866942,
                "url": "https://finnhub.io/api/news?id=67631bafdf38a6e424b16afae605f0c6073132b0aa502c97ab9d6a2ef2e274bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783719905,
                "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140865011,
                "url": "https://finnhub.io/api/news?id=da214c6fd8d23b4dd37c80c7d483172cf970e4a98b72e72eb896b08e27b9522a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1783710603,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140865338,
                "url": "https://finnhub.io/api/news?id=d9b3d4cd98409619ec0c5882fdbae7aa759d05b52654942e444b7f2574d8fe0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 10, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bladde",
                "category": "company",
                "datetime": 1783707000,
                "headline": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)"
              },
              {
                "id": 140863713,
                "url": "https://finnhub.io/api/news?id=f1b2c2cebd6715831501571f2e0eaa6df6e4dbd5dd50cb7f5e5c18fd5cf66369",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1783701603,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140873796,
                "url": "https://finnhub.io/api/news?id=0834007187294a8053c5d6a0363f926567aaeaf14150e2b0570182de30af9b82",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin",
                "category": "company",
                "datetime": 1783680561,
                "headline": "FDA Approves Pembrolizumab Or Pembrolizumab And Berahyaluronidase Alfa-pmph Each With Enfortumab Vedotin-ejfv For Muscle Invasive Bladder Cancer"
              },
              {
                "id": 140858499,
                "url": "https://finnhub.io/api/news?id=ff62adc1f5e4e9e24af6163944e028e2aa4af7750f6f1d35af5cd06ac29fb9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.",
                "category": "company",
                "datetime": 1783639802,
                "headline": "This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026"
              },
              {
                "id": 140854740,
                "url": "https://finnhub.io/api/news?id=f01e0b0e06127f9e5fd58bae5a86a0425327da12f5e1693b13c85b4dd00602d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.",
                "category": "company",
                "datetime": 1783621260,
                "headline": "EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?"
              },
              {
                "id": 140853541,
                "url": "https://finnhub.io/api/news?id=9a62fecb6a6ef6aed8786ef4f4918bf9259eb119c510f5913306141e4b4334e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Key opportunities in the Southeast Asia oncology drug access market involve prioritizing accessibility, affordability, and availability of therapies through government initiatives, biosimilar adoption, and patient assistance programs. Collaboration among stakeholders enhances access to innovative treatments, while advancements in precision oncology drive growth, despite challenges like high costs and regulatory complexities.Dublin, July 09, 2026 (GLOBE NEWSWIRE) -- The \"Southeast Asia Oncology D",
                "category": "company",
                "datetime": 1783612380,
                "headline": "Southeast Asia Oncology Drug Access Market Now Available; Profiles Roche, AstraZeneca, Merck, and Other Key Peers"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140862237,
                "url": "https://finnhub.io/api/news?id=4b7955e8a026bc3a0e050b7dd7695262c9d1ae69b00a6ccc30afeae331b3ce89",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Merck &amp; Co (NYSE:MRK) with a Equal-Weight and raises the price target from $112 to $113.",
                "category": "company",
                "datetime": 1783603109,
                "headline": "Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $113"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140852182,
                "url": "https://finnhub.io/api/news?id=44e3f9e8461045391c4a83bc13f1bc62e5628bbd2f31024755d11d0d0b36d472",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783602006,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140851673,
                "url": "https://finnhub.io/api/news?id=e2e9434a4678dfc4b99977f73b96b17f95ea6c8f42841d8dcffe450c72dc44d8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/09/Dallas--Tx---August-5--2022-Senator-Rick.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Scott urges Trump admin to increase tariffs on Chinese generic drug makers, citing forced labor &amp; safety concerns. Calls for accountability.",
                "category": "company",
                "datetime": 1783572093,
                "headline": "Rick Scott Urges Trump to Increase Tariffs on Chinese Generic Drug Makers Over 'Uyghur Slave Labor' Claims"
              },
              {
                "id": 140846351,
                "url": "https://finnhub.io/api/news?id=f04de45506b1a90b3aaccb38d94091579d0f7a89baec41e482f1e15044ce0b0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has reached a new access agreement with the ADAP Crisis Task Force for its once daily HIV treatment IDVYNSO. This development gives investors fresh context for assessing the stock. See our latest analysis for Merck. Merck shares recently pulled back, with a 1-day share price return declining 2.23% to close at US$125.99. However, the 30-day share price return of 5.41% and 1-year total shareholder return of 55.54% point to momentum that remains broadly positive. If Merck’s recent...",
                "category": "company",
                "datetime": 1783548990,
                "headline": "Merck (MRK) Gets New HIV Access Deal As Its Valuation Narrative Stays In Focus"
              },
              {
                "id": 140845513,
                "url": "https://finnhub.io/api/news?id=549a6b89bc122af3450e9e6b2e9dafa75bced723502ae900d2404bf032669cec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast cancer and EU approval of KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. These approvals further entrench KEYTRUDA at the center of Merck’s cancer portfolio, broadening its use across hard-to-treat tumors while the company prepares for future loss of...",
                "category": "company",
                "datetime": 1783545346,
                "headline": "Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?"
              },
              {
                "id": 140845480,
                "url": "https://finnhub.io/api/news?id=cad5ed53bd8a2b4b54d307f8fa766bc06c0d53359b5fdc9884250cb3c2debfec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tesla, Bank of America and Merck lead today's featured research, highlighting growth drivers, risks and outlooks shaping these widely watched stocks.",
                "category": "company",
                "datetime": 1783542540,
                "headline": "Top Research Reports for Tesla, Bank of America & Merck"
              },
              {
                "id": 140844150,
                "url": "https://finnhub.io/api/news?id=9f5dbca0860c023f09bac87bc2eaea6090b20867b27cdb9d40ab07f3c5d97a89",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1783537803,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140844401,
                "url": "https://finnhub.io/api/news?id=1e6f7b15e160167e71834984cc3c9da524bf2f444e60c4777d8c0607565d09f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The chipmaker signaled a major turn in its business, and the market bought it. Now comes the hard part: proving the rally can last.",
                "category": "company",
                "datetime": 1783535858,
                "headline": "Texas Instruments Stock Is Running On A Bold Promise"
              },
              {
                "id": 140843423,
                "url": "https://finnhub.io/api/news?id=2702b66ac2ac5c03c36756010c05b66cc8e79917f95f9b0300663e0c8fe0c4a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "By Karen Roman Redwire Corporation (NYSE: RDW) said it designated Paul Reichert and Niki Werkheiser to serve at strategic advisory roles at Space Microgravity Development (SpaceMD), Redwire’s venture company focused […]",
                "category": "company",
                "datetime": 1783530982,
                "headline": "Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140840493,
                "url": "https://finnhub.io/api/news?id=684da8d2a4e5f5ee2cdba89a999ca639b2c146877af8d6e1d7fb5e72a1957ecb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.",
                "category": "company",
                "datetime": 1783513500,
                "headline": "MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?"
              },
              {
                "id": 140839611,
                "url": "https://finnhub.io/api/news?id=aa1b4335fc7f96b4f86da9d5bd3b6e46b4e6fb934699e65c033594c66b519837",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "JACKSONVILLE, Fla., July 08, 2026--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focused o",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities"
              },
              {
                "id": 140846132,
                "url": "https://finnhub.io/api/news?id=219d003d42a175c0c2d370c0eaf041a94b7de499a8353c7b6222a81d8d1b01de",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "RBC Capital  analyst Trung Huynh   reiterates Merck &amp; Co (NYSE:MRK) with a Outperform and maintains $142 price target.",
                "category": "company",
                "datetime": 1783504236,
                "headline": "RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target"
              },
              {
                "id": 140840980,
                "url": "https://finnhub.io/api/news?id=f6b89872007a09af68ad6c31154624cb9a96d205fade79b74bd2350ac6679dce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/08/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay&#39;s cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.",
                "category": "company",
                "datetime": 1783500020,
                "headline": "Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 140846134,
                "url": "https://finnhub.io/api/news?id=fb1f3b42e8de991b4bd303aac18ec1763330d32a0b0ad31f39955562dafe8bbf",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Merck &amp; Co (NYSE:MRK) with a Overweight and raises the price target from $145 to $150.",
                "category": "company",
                "datetime": 1783492914,
                "headline": "Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $150"
              },
              {
                "id": 140833906,
                "url": "https://finnhub.io/api/news?id=8b4af97dddd3317a50c1206ecb3fecd7ad2f983ec27a7e1c72a78c4e14a73ff1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1783451403,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140830563,
                "url": "https://finnhub.io/api/news?id=db2174c073837831286ca2c07c1b3b00b29ddae31ee4aaebfa28b835704e34e6",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1783420110,
                "headline": "SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn"
              },
              {
                "id": 140830044,
                "url": "https://finnhub.io/api/news?id=a525b2f107ac14ff07317a5d0fd2a984f07cf0426b0135b325b8d65da9b43696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.",
                "category": "company",
                "datetime": 1783413771,
                "headline": "Can anyone catch up to Eli Lilly?"
              },
              {
                "id": 140825364,
                "url": "https://finnhub.io/api/news?id=3462254cc01a429463310b2473d7a1b5e4b5e87bc51e87c16d916a740ef0bc24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.",
                "category": "company",
                "datetime": 1783374605,
                "headline": "Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140824128,
                "url": "https://finnhub.io/api/news?id=755bfac8086b55458ed003b38133dd776e18096e6e6946c3c4a4bc64ae17e627",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.",
                "category": "company",
                "datetime": 1783371901,
                "headline": "Which S&P500 stocks are showing activity after the closing bell on Monday?"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140823275,
                "url": "https://finnhub.io/api/news?id=aacc08c69cab6b9db8a0b9bbabb6718315106d78c1d7f115fc1eb8077d774c13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Monday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1783365003,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 140823501,
                "url": "https://finnhub.io/api/news?id=ea549e3b52e2e94af16a616297f7a713296a52a22cf774b483df1bb0afc662c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones index fell but other indexes rallied as President Trump made bullish comments. Microsoft fell on the stock market today while Micron rose.",
                "category": "company",
                "datetime": 1783364029,
                "headline": "Stock Market Today: Dow Up, AI Stock Tests Entry; TeraWulf Cedes Key Level Despite Anthropic Deal (Live Coverage)"
              },
              {
                "id": 140823613,
                "url": "https://finnhub.io/api/news?id=6b219e38084e6475784ec645d74c2fa22bed3720375dabbf7ff1d4559a279cdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.",
                "category": "company",
                "datetime": 1783362960,
                "headline": "Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?"
              },
              {
                "id": 140821033,
                "url": "https://finnhub.io/api/news?id=4c61cc364714533bd4f04c0f59c93534543bbcf3cc26ac7b0713b270e8efaada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.",
                "category": "company",
                "datetime": 1783352496,
                "headline": "Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings"
              },
              {
                "id": 140824936,
                "url": "https://finnhub.io/api/news?id=89bd33c0e677d2320cedd19adf8992de1bb1e9b573a15c20c0d361d0e1d5ffa6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV &amp; oncology potential.",
                "category": "company",
                "datetime": 1783346723,
                "headline": "Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says"
              },
              {
                "id": 140824618,
                "url": "https://finnhub.io/api/news?id=1cd268edbc835f22e1ed85b0dc0df50fb53a9d0098a14558c26e1aa4b1f18494",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783344935,
                "headline": "8 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140818670,
                "url": "https://finnhub.io/api/news?id=5bb378871c4d7250110c755b530ad54ad40bcf2da5fe3ace6f349cc9076ef393",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_48_b0208efde3.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Thursday's jobs report came in far below forecasts, initially easing pressure on the Federal Reserve, before a fresh slide in memory and semiconductor stocks dragged the Nasdaq lower even as the Dow closed at a record. Tesla sold off despite its best delivery quarter in years, healthcare names caught a bid, and SK Hynix lined up what would be the largest US listing ever by a foreign company.",
                "category": "company",
                "datetime": 1783331949,
                "headline": "Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway."
              },
              {
                "id": 140824938,
                "url": "https://finnhub.io/api/news?id=92921093c423eb00b73c135e6be39d773b9285a26371027163ca311cdc2c9177",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Merck &amp; Co (NYSE:MRK) with a Neutral and maintains $120 price target.",
                "category": "company",
                "datetime": 1783329296,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Merck & Co, Maintains $120 Price Target"
              },
              {
                "id": 140814545,
                "url": "https://finnhub.io/api/news?id=7762ea644fb03778da654b93f7dfa933d7c1234ba00dfef0d0d4b7426470cfe5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year",
                "category": "company",
                "datetime": 1783273647,
                "headline": "Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year"
              },
              {
                "id": 140809717,
                "url": "https://finnhub.io/api/news?id=0b887c1c3a57dcb3dbfc0bad12474feac5feee8d09492eb3cc296408add23f4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ulcerative colitis. The company announced new FDA approvals for KEYTRUDA-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer. Regulatory authorities in the EU also cleared additional KEYTRUDA combinations in early-stage oncology settings. For investors tracking NYSE:MRK, these updates sit at the core of what drives long term value for a...",
                "category": "company",
                "datetime": 1783206585,
                "headline": "Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test"
              },
              {
                "id": 140800044,
                "url": "https://finnhub.io/api/news?id=6a64d2682b456ce39b982ce5c7ed3f119bd9b7219dd3dc983948bba84dd903d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.",
                "category": "company",
                "datetime": 1783092855,
                "headline": "Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140801112,
                "url": "https://finnhub.io/api/news?id=5d0fcbac5cc5b764db3a7a66357d599a00971ea60c0776def7e158542f3aa154",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.",
                "category": "company",
                "datetime": 1783092720,
                "headline": "MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?"
              },
              {
                "id": 140798353,
                "url": "https://finnhub.io/api/news?id=af3ce6803222543543796d3613fb7b8ebe9f7614e6f6a9734ddef35d29886348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21 Billion in 2025 and is expected to reach USD 115.02 Billion in 2026 and is expected to reach around USD 309.84 Billion by 2035, at a CAGR of 11.62% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Eli Lilly and Company,",
                "category": "company",
                "datetime": 1783067400,
                "headline": "[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140794037,
                "url": "https://finnhub.io/api/news?id=d34b320aa80113fce02e54c7d0e2a3e9dd50198bf09c66427dc6a9583845cac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State",
                "category": "company",
                "datetime": 1783020874,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140793731,
                "url": "https://finnhub.io/api/news?id=55486704e2baf952e730ef71d9723dbe5aeba01b04fb13956ad7d7c40bd38f58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1783019404,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 140794032,
                "url": "https://finnhub.io/api/news?id=f4b49dc8a4155423aba64d44bfeefe3141a39ead48c7fb63d3305a6de9a47c89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.",
                "category": "company",
                "datetime": 1783015478,
                "headline": "Merck Stock, JPMorgan And Two Others Hit New Highs"
              },
              {
                "id": 140795133,
                "url": "https://finnhub.io/api/news?id=52987caaba1d0a4214a3d3520e4a63c4492060fd2ae8de73a16ba58c60747c14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Explore this week’s dividend updates.",
                "category": "company",
                "datetime": 1783015043,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 5"
              },
              {
                "id": 140792979,
                "url": "https://finnhub.io/api/news?id=e3abb4735d28fe1ce35ae74f2a97593a9c387c3bc2375ef13f3b1e09dbb5d3b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S",
                "category": "company",
                "datetime": 1783014167,
                "headline": "Sector Update: Healthcare Stocks Gain Thursday Afternoon"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140793732,
                "url": "https://finnhub.io/api/news?id=02d33b3c3c02f1c3de9c4f770927cb1f940697516e24678c4d052b42bf8c0196",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268780783/image_2268780783.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. analysis: fairly valued after YTD rally as Keytruda & Winrevair lift guidance. Click for this updated look at MRK and see if it is right for you.",
                "category": "company",
                "datetime": 1783005739,
                "headline": "Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up"
              },
              {
                "id": 140800595,
                "url": "https://finnhub.io/api/news?id=d496e3fa576899848e38d53aa49bd5f7bcaf860c9b143f35ea2324fecbf3ac1c",
                "image": "https://image.cnbcfm.com/api/v1/image/108330186-1783019122904-1783018967-46914473154-hd.jpg?v=1783019124&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Jeff Kilburg, founder and CEO of KKM Financial, joins \"Power Lunch\" to discuss the growing interest in healthcare stocks.",
                "category": "company",
                "datetime": 1783004742,
                "headline": "KKM's Jeff Kilburg explains the healthcare trade in the second half of 2026"
              },
              {
                "id": 140785879,
                "url": "https://finnhub.io/api/news?id=68140cf16a5d7028256e4f2b2dcbd36c46c874bb868a7c0962444eafa0a1e070",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck cited business reasons for the discontinuation of the investigational drug.",
                "category": "company",
                "datetime": 1782943304,
                "headline": "MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership"
              },
              {
                "id": 140792449,
                "url": "https://finnhub.io/api/news?id=61b321aff28d9e37c54b5110047f1cec1b326ca8b0f5ed7545a9e24fa3530c17",
                "image": "https://image.cnbcfm.com/api/v1/image/108329655-4ED3-MM-D-BLOCK-070126.jpg?v=1782947477&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.",
                "category": "company",
                "datetime": 1782934819,
                "headline": "Moderna's now got a lot going for it, says Jim Cramer"
              },
              {
                "id": 140783353,
                "url": "https://finnhub.io/api/news?id=8d8d4dbcd75e54bc1136dbce779a2713eac74a23a63c39b81cb0c347fdd45387",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1782933003,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 140792450,
                "url": "https://finnhub.io/api/news?id=b96976863ba687c527e49a3f43a3026e48124bf4d995f19dca177bd6671423b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108000894-1771434677666-108000894-1719932078582-gettyimages-2151784856-MODERNA_RSV_VACCINE.jpg?v=1771437699&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.",
                "category": "company",
                "datetime": 1782931819,
                "headline": "Jim Cramer says this former Covid market darling is finally investable again"
              },
              {
                "id": 140778779,
                "url": "https://finnhub.io/api/news?id=8450ad65d118343e8b422f14c5f3604af12f7054f08f4f6feb9b5a358c47f318",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?",
                "category": "company",
                "datetime": 1782906601,
                "headline": "Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140778806,
                "url": "https://finnhub.io/api/news?id=e6d11565509c7fc0723e438a4219e8df330054a0e47e77f2a719d7c7e7e10306",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., July 01, 2026--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4",
                "category": "company",
                "datetime": 1782902700,
                "headline": "Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4"
              },
              {
                "id": 140776953,
                "url": "https://finnhub.io/api/news?id=61b39c4de285b126d1370ef4287e5453adabfc0c48b650c80cb7a80df194c9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Association for the Accreditation of Human Research Protection Programs has awarded full accreditation to five more entities, including the U.S. health professions academy and one of the world's leading pharmaceutical companies. The newly accredited entities are:",
                "category": "company",
                "datetime": 1782875400,
                "headline": "AAHRPP Accredits Five More Research Entities"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140774512,
                "url": "https://finnhub.io/api/news?id=60d4e872b38b8a51020c9e003ba137fc0486811d85f7026d6e974ba19d46aa88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%",
                "category": "company",
                "datetime": 1782848500,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 140775621,
                "url": "https://finnhub.io/api/news?id=ba4bee7973b33d1ab47b1c5bd0bd439d3450cca266c881f93fcb051a7eb2bf2d",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782842568,
                "headline": "Verizon Leads July's 'Safer' Dogs Of The Dow; Nike Near 'Ideal'"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140773529,
                "url": "https://finnhub.io/api/news?id=91b4ae92589b2d9ea19e8b779447047ca848480cd0fa312ab704a6fb7f0dab03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. lawmakers have opened national security investigations into Merck's clinical trial activities in China. The probes focus on trials conducted in politically sensitive regions, including Xinjiang, and at hospitals linked to the Chinese military. Key concerns include intellectual property protection, ethical oversight, and the handling of sensitive biotechnology data. Merck, listed as NYSE:MRK, is a large global pharmaceutical company with a heavy focus on prescription medicines,...",
                "category": "company",
                "datetime": 1782839197,
                "headline": "Merck (MRK) Faces U.S. Security Probe Over China Clinical Trials"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140772851,
                "url": "https://finnhub.io/api/news?id=7831567aa0ddc4cfcc09a725c5a9c933c5dc83303d23c0b0f4f928d6a5657a5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's (MRK) upcoming phase 3 OptiTrop-Lung06 readout could establish SAC-TMT as a chemotherapy rep",
                "category": "company",
                "datetime": 1782832053,
                "headline": "Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says"
              },
              {
                "id": 140775064,
                "url": "https://finnhub.io/api/news?id=02108edcb5c3c19ddb4166472d2697a0109d53eddc73f4cf08f9c2cf976cda9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "B of A Securities  analyst Tim Anderson   maintains Merck &amp; Co (NYSE:MRK) with a Buy and raises the price target from $130 to $141.",
                "category": "company",
                "datetime": 1782826795,
                "headline": "B of A Securities Maintains Buy on Merck & Co, Raises Price Target to $141"
              },
              {
                "id": 140781677,
                "url": "https://finnhub.io/api/news?id=ab65f7a3201d95ef11cd96835570ff682d86a3d9510e670ecc990714c0d3509f",
                "image": "https://image.cnbcfm.com/api/v1/image/108264191-1770764453454-gettyimages-2259521349-img_7851.jpeg?v=1770764487&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782825385,
                "headline": "Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more"
              },
              {
                "id": 140771981,
                "url": "https://finnhub.io/api/news?id=1b0f26a15d0484950f3723cd1a9eeaeda916aa55b962ae7710464a962924f4e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang",
                "category": "company",
                "datetime": 1782824140,
                "headline": "Merck, AbbVie investigated over China military hospital drug trials"
              },
              {
                "id": 140772002,
                "url": "https://finnhub.io/api/news?id=50be84fb33f2632af8f65895891eccf8c50463a9cb8fe133ab23138261a1c821",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?",
                "category": "company",
                "datetime": 1782821103,
                "headline": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140771584,
                "url": "https://finnhub.io/api/news?id=6c754633791e8e46d89dc976069416ae410eb3a21e59837ad76cd1b1e0936bb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous",
                "category": "company",
                "datetime": 1782819184,
                "headline": "Market Chatter: AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China"
              },
              {
                "id": 140775065,
                "url": "https://finnhub.io/api/news?id=27789a54ddee9badae264cf469a6b54f0adbbb7ec05dc6b2a6315c1daa71b429",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Scotiabank  analyst Louise Chen   maintains Merck &amp; Co (NYSE:MRK) with a Sector Outperform and raises the price target from $136 to $155.",
                "category": "company",
                "datetime": 1782816597,
                "headline": "Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $155"
              },
              {
                "id": 140781710,
                "url": "https://finnhub.io/api/news?id=3df3441b99c591d54c3f5c8a360b236c02f57bee97df464f2bc66c2ef6f772a3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328691-3ED1-REQ-063026-NewsOPEN.jpg?v=1782827583&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1782813641,
                "headline": "Market Open: June 30, 2026"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140772369,
                "url": "https://finnhub.io/api/news?id=e00ce0091248ea12ffc6edc03cf742025d4e18a34a9a0f800f183d3a3e993f4c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Abbvie.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.",
                "category": "company",
                "datetime": 1782810790,
                "headline": "Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report"
              },
              {
                "id": 140781711,
                "url": "https://finnhub.io/api/news?id=02d91ccebaaebf5085bf9b485c8b12d7b5bd1bd29f0076b7a6472ba09dd6d4c7",
                "image": "https://image.cnbcfm.com/api/v1/image/107384812-1709909242625-gettyimages-1124366588-20190212-dm-gtyworldagexpo-05.jpeg?v=1751374629&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1782804461,
                "headline": "Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more"
              },
              {
                "id": 139930306,
                "url": "https://finnhub.io/api/news?id=7c7bc27315adbe5bcfe5ed5e35cd4e6dcc9d016797069c983e56b5235fa1d71d",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782799815,
                "headline": "How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To Thank"
              },
              {
                "id": 140781757,
                "url": "https://finnhub.io/api/news?id=5baed29654721b5d98fe3ce501ae03081ebb89e584dc62b245c3de70b534c11e",
                "image": "https://image.cnbcfm.com/api/v1/image/108262197-1770323920909-gettyimages-2260105869-bb1_2632_uxvikxrq.jpeg?v=1782775477&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The Dow rose more than 300 points on Monday to post its first close above 52,000. Alphabet, a new addition to the 30-stock index, jumped almost 5%.",
                "category": "company",
                "datetime": 1782760725,
                "headline": "Tuesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140765446,
                "url": "https://finnhub.io/api/news?id=d9ce9227f83812c8375c292a2411e4b04a0dca1e07fcfea1c6517855e3ae1b31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.",
                "category": "company",
                "datetime": 1782752520,
                "headline": "MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines"
              },
              {
                "id": 140762604,
                "url": "https://finnhub.io/api/news?id=2721bf0ff4ee829f4aadac8e52d2a889b76b2f9c38ae921e9e650d42dd5dedc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1782739806,
                "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?"
              },
              {
                "id": 140763353,
                "url": "https://finnhub.io/api/news?id=1f7f419f3bbad927aef061ca6d26d67e1cd18b1b1b987034a5656bdefd9c12f3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328213-17827514121782751407-46849797479-1080pnbcnews.jpg?v=1782751411&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's \"Halftime Report\" team debate the end of the quarter and discuss their trading strategy heading into the second half of the year.",
                "category": "company",
                "datetime": 1782738106,
                "headline": "'Halftime' traders debate the market setup for the next half of 2026"
              },
              {
                "id": 140761605,
                "url": "https://finnhub.io/api/news?id=711bbcaa4e6c6f8f4def15798e9b51c879c48983f3b74c54917a4d6ed5a4b9bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782735720,
                "headline": "Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?"
              },
              {
                "id": 140761567,
                "url": "https://finnhub.io/api/news?id=e4fd842930c69b4cb1219cad2efac884044ac9b9e4bb65154af4b5903dc71e21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782733560,
                "headline": "Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?"
              },
              {
                "id": 140760729,
                "url": "https://finnhub.io/api/news?id=300b30523bfcd6ad0bb54ec19ad0bfcca200e7c34eba942e0c0d2964684a429b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Nasdaq 100 futures advanced more than 1% in premarket trade after tech stocks shed nearly 5% last week",
                "category": "company",
                "datetime": 1782732787,
                "headline": "S&P 500 Nasdaq futures rise after U.S.-Iran pause June 2026"
              },
              {
                "id": 140760836,
                "url": "https://finnhub.io/api/news?id=552695bf793ba252b3b2ca8b51026f1fce9a3dffdba15c9f7207092b1de227e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 29, 2026--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.",
                "category": "company",
                "datetime": 1782729900,
                "headline": "Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV"
              },
              {
                "id": 140762948,
                "url": "https://finnhub.io/api/news?id=d5667ff3dc444911aa93f22458176bb0017d39392aa80bfb4a7b359fdca46bed",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individualsMerck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced an agreement",
                "category": "company",
                "datetime": 1782715664,
                "headline": "Merck Agrees With ADAP Crisis Task Force To Help State AIDS Drug Assistance Programs Provide Access To Once-Daily HIV Treatment, IDVYNSO"
              },
              {
                "id": 140763428,
                "url": "https://finnhub.io/api/news?id=92a429b37c231d9f5231f399145e88c19987d9fbc67df37ba0a7d7744eb5e2a8",
                "image": "https://image.cnbcfm.com/api/v1/image/108326264-17823199802026-06-24t160038z_1026825060_rc2d0mafrueq_rtrmadp_0_usa-stocks.jpeg?v=1782320413&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Stocks rose Monday as investors weighed a pause in hostilities between the U.S. and Iran.",
                "category": "company",
                "datetime": 1782669838,
                "headline": "Dow jumps more than 200 points as U.S.-Iran halt hostilities, Alphabet shares gain: Live updates "
              },
              {
                "id": 140753990,
                "url": "https://finnhub.io/api/news?id=fce43d52df7f57adcf19b0141f93fe4ff31409260163bd796f09da38fba70f7a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264471660/image_2264471660.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Schwab US Dividend Equity ETF offers mature, profitable businesses at a blended P/E of 15.6x, a significant discount to the S&P 500. Click for more on SCHD.",
                "category": "company",
                "datetime": 1782639000,
                "headline": "It's Time To Go All-In On SCHD"
              },
              {
                "id": 140750602,
                "url": "https://finnhub.io/api/news?id=f27f6b207bda2bcdc279e668a6badafa286297ecc1fd4ccaff83dd1b21071abd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]",
                "category": "company",
                "datetime": 1782605263,
                "headline": "Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC"
              },
              {
                "id": 140741514,
                "url": "https://finnhub.io/api/news?id=a9b2ccd9c36d16b4a7fae37b8185475d6136f42de99ad8853ea71a7729216c1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Wondering whether Merck at US$128.66 is still offering fair value, or if the recent run means you are paying too much for the stock? The share price moves have been strong, with Merck showing returns of 13.0% over 7 days, 7.0% over 30 days, 20.9% year to date and 68.1% over the past year, in addition to longer term returns of 22.3% over 3 years and 91.3% over 5 years. Recent headlines around Merck have kept the stock in focus and reinforced investor attention on its long term prospects and...",
                "category": "company",
                "datetime": 1782511739,
                "headline": "Merck (MRK) Stock Weighs Strong Rally Against Mixed Valuation Signals"
              },
              {
                "id": 140741515,
                "url": "https://finnhub.io/api/news?id=8d9644330c3b8a7b4423042e3f8abe71673405c6d3704294d62da69c3d399984",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.",
                "category": "company",
                "datetime": 1782510304,
                "headline": "Merck (MRK) Gains As Market Dips: What You Should Know"
              },
              {
                "id": 140746824,
                "url": "https://finnhub.io/api/news?id=831a4124991b2786a798864184e8fb4efcc4b4b5c724b52fafff675365e108f1",
                "image": "https://image.cnbcfm.com/api/v1/image/108327759-17825112941782511292-46793441687-1080pnbcnews.jpg?v=1782511293&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s “Fast Money” team shares their final trades of the day.",
                "category": "company",
                "datetime": 1782497183,
                "headline": "Final Trade: GM, XLV, MRK, SPCX"
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140741516,
                "url": "https://finnhub.io/api/news?id=c52d398d2b5710d0f99c0173129e8151ad7aead20b89218f39213d283f70ec62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?",
                "category": "company",
                "datetime": 1782494910,
                "headline": "The $11 Billion Reason TECH Stock Is Up Today"
              },
              {
                "id": 140746796,
                "url": "https://finnhub.io/api/news?id=fe15595f4953f27cc4b58c74d5c83ff2d2864a24e30ace17bb82dd2bdc1827df",
                "image": "https://image.cnbcfm.com/api/v1/image/108327725-17825072231782507209-46792477115-1080pnbcnews.jpg?v=1782507222&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.",
                "category": "company",
                "datetime": 1782493286,
                "headline": "Why BMO's Siegerman says Merck is a top healthcare stock pick"
              },
              {
                "id": 140737993,
                "url": "https://finnhub.io/api/news?id=4ec7a0224ab0405979874fb3b438152890cd9bb8fada3b210159c9b7b2acaaad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.",
                "category": "company",
                "datetime": 1782489808,
                "headline": "AbbVie Stock's Growth Story Has One Question Mark"
              },
              {
                "id": 140738042,
                "url": "https://finnhub.io/api/news?id=f8b316ddbf026bf067b5337eb62e61e0db952dee0b18064b45a8553ecf61881b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?",
                "category": "company",
                "datetime": 1782489673,
                "headline": "Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?"
              },
              {
                "id": 140738319,
                "url": "https://finnhub.io/api/news?id=836bcfe7c2e7088a1d512d316d935002acddd7e4f3d6233f67bdf2745c49da75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160887573/image_1160887573.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Micron goes volatile on great news, SpaceX the bellwether and Fed interest rate commentary.",
                "category": "company",
                "datetime": 1782483240,
                "headline": "Wall Street Roundup: What Isn't Priced In?"
              },
              {
                "id": 140738484,
                "url": "https://finnhub.io/api/news?id=ef5060389f60276f62729917f5f1870ad05f242bbb0eaf9b66b4ccc315ed7ca7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.cdc.gov/ebola/situation-summary/index.html",
                "category": "company",
                "datetime": 1782479453,
                "headline": "CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low"
              },
              {
                "id": 140736489,
                "url": "https://finnhub.io/api/news?id=ef5d826f2613b98deb5161d09e1d52995b18f500b121370048657125da8de6cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1782478806,
                "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140736490,
                "url": "https://finnhub.io/api/news?id=da3c5fb9cd6fcd9972234207c964aa1996e4a20ce9d71fbece3028444dd6b146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782478800,
                "headline": "Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?"
              },
              {
                "id": 140734602,
                "url": "https://finnhub.io/api/news?id=75a2245510d373a6d6c50defb3e2c0bb9b28a68cf403c213f8026e5b42c2364d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]",
                "category": "company",
                "datetime": 1782472268,
                "headline": "Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results"
              },
              {
                "id": 140735129,
                "url": "https://finnhub.io/api/news?id=8f1bf596ce182e56e350eee0da5f22dee126d24c8d2f65b0f0da933c699ddae7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260722103/image_2260722103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Jazz Pharmaceuticals' shares are in the distribution phase because Zepzelca failed to show a survival benefit over irinotecan. See why JAZZ stock is downgraded to hold.",
                "category": "company",
                "datetime": 1782465751,
                "headline": "Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)"
              },
              {
                "id": 140736177,
                "url": "https://finnhub.io/api/news?id=70ba6349f55e6c169bedab13e6f19866634ca1540b8b3e27a10416cb9ab8f55b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/26/Qualcomm.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Jim Lebenthal suggests investing in Qualcomm on CNBC&#39;s Halftime Report, while Stephanie Link chose Rockwell Automation.",
                "category": "company",
                "datetime": 1782459159,
                "headline": "Qualcomm, Merck, Rockwell Automation And A Real Estate Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140738043,
                "url": "https://finnhub.io/api/news?id=a91060899654895f2c29f9a74f86e0fbe5dd804cdb74c4c8577009e830fed0e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.",
                "category": "company",
                "datetime": 1782446460,
                "headline": "Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal"
              },
              {
                "id": 140732215,
                "url": "https://finnhub.io/api/news?id=1011afe06ab0dcb1ee22df6c23045e72aa8b02ac4e24a7896a5b564ca2bb6f22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]",
                "category": "company",
                "datetime": 1782443886,
                "headline": "Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger"
              },
              {
                "id": 140729450,
                "url": "https://finnhub.io/api/news?id=adb40a383a2e09f0f626b3f872c4ce91a962c239c4a12c08f8da43c1f3995ea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1782417238,
                "headline": "Candel Therapeutics Designates Mark Sims as CCO"
              },
              {
                "id": 140728307,
                "url": "https://finnhub.io/api/news?id=6156b9c7e94fbc96f2c772f6ca588b01f30909829d24a93ad278d456696ed7ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).",
                "category": "company",
                "datetime": 1782414935,
                "headline": "Big Tech stocks tumble while Micron continues to gain on Q3 earnings"
              },
              {
                "id": 140729452,
                "url": "https://finnhub.io/api/news?id=13b5af933eca7bd4760ac13e68e51ca50be6bc0cf7e898fba0d439162a3770b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged Thursday after Germany’s  Merck KGaA  announced it agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the  for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782414720,
                "headline": "Bio-Techne Is a Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company."
              },
              {
                "id": 140728193,
                "url": "https://finnhub.io/api/news?id=8812f369e1c746da48a498d89ecec0b3727d6002df6251389f0d5edede169eb4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1782414604,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 140728429,
                "url": "https://finnhub.io/api/news?id=5b587aba6b3e9cd920adca306a24a5151cd34ebe0ef214f66040c931402b6234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Fred Alger Management, LLC (\"Alger\"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (\"Index\"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective.",
                "category": "company",
                "datetime": 1782414000,
                "headline": "Alger Russell Innovation Index Updates for Second Quarter 2026"
              },
              {
                "id": 140726156,
                "url": "https://finnhub.io/api/news?id=6b6ac7dc515d60883d5ed0e2ae4b17ad9689a83d2763c59fd758ba8dd4810dfe",
                "image": "",
                "source": "Fintel",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782404866,
                "headline": "CICC Initiates Coverage of Merck (MRK) with Outperform Recommendation"
              },
              {
                "id": 140725573,
                "url": "https://finnhub.io/api/news?id=80e91ccc77cd3a7657c698a7e1f0f4a3aae504e29025f6ea0f407e423646f060",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas",
                "category": "company",
                "datetime": 1782402056,
                "headline": "Top Midday Stories: Micron Shares Soar After Estimate-Topping Earnings Results; Bio-Techne to be Acquired by Merck for $11.3 Billion"
              },
              {
                "id": 140727299,
                "url": "https://finnhub.io/api/news?id=c475adbeccd67d5849385444c6edbf827f5552c084194728e669f22c32033269",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The S&P 500 index was up about 0.3%, while the Nasdaq Composite fell 0.4%.",
                "category": "company",
                "datetime": 1782400321,
                "headline": "Dow Soars Over 750 Points, Hits Record High As Investors Look Beyond Tech Stocks — PCE Inflation Comes In Hottest Since October 2023"
              },
              {
                "id": 140725717,
                "url": "https://finnhub.io/api/news?id=9ba5a4e89ab45507420ec3554c35e1301000068556095a6539f53d642de20357",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged Thursday after Germany’s  Merck KGaA  announced it agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 19% to $70.25 on Thursday, leading the  for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782397800,
                "headline": "Bio-Techne Is Today’s Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company."
              },
              {
                "id": 140725718,
                "url": "https://finnhub.io/api/news?id=c169edde559d1849c06624b07afcaf68caadaaf32779f39fe99cf79577c5bb82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.",
                "category": "company",
                "datetime": 1782397344,
                "headline": "Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion"
              },
              {
                "id": 140725719,
                "url": "https://finnhub.io/api/news?id=219e37537f2ba78d10f1c40efee004ae81a92833455fb224483337b6e48b659d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.",
                "category": "company",
                "datetime": 1782397140,
                "headline": "Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use"
              },
              {
                "id": 140725720,
                "url": "https://finnhub.io/api/news?id=a346fb06878946df84b361ac6cf8e147819535aaa49b566713e29cf2e293446c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.",
                "category": "company",
                "datetime": 1782396240,
                "headline": "MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer"
              },
              {
                "id": 140726733,
                "url": "https://finnhub.io/api/news?id=cbef7ca64e81f74d3e6a7982fb09e629469de23e7a6c3b7965d6951cf5e76dd0",
                "image": "https://image.cnbcfm.com/api/v1/image/108326946-17824069151782406912-46768080827-1080pnbcnews.jpg?v=1782406913&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The Investment Committee give you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1782393530,
                "headline": "Final Trades: Qualcomm, Rockwell Automation, Merck and Simon Property Group"
              },
              {
                "id": 140724627,
                "url": "https://finnhub.io/api/news?id=b9fbde41b210d86c06c3b17cb5bc6f9ee435d1fe6a80d089b018599fc63f167f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with",
                "category": "company",
                "datetime": 1782392828,
                "headline": "Bio-Techne to Be Acquired by Germany's Merck in $11.3 Billion Deal"
              },
              {
                "id": 139939358,
                "url": "https://finnhub.io/api/news?id=4f94d0fc9b1e70b1626ced271fdf34107fd56fba4b23b4c8fcf9095715ba0041",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1782392476,
                "headline": "Live On CNBC, Josh Brown Hosts Segment Titled \"Josh's Best Stocks In The Market: Realty Income, Prologis, Simon Property Group\""
              },
              {
                "id": 140724628,
                "url": "https://finnhub.io/api/news?id=e60e0d53c29cae6a62405f595805fcb0a85ab2d24a77ac35334cdf053e7f339c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]",
                "category": "company",
                "datetime": 1782392426,
                "headline": "REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan"
              },
              {
                "id": 140726459,
                "url": "https://finnhub.io/api/news?id=4fa9ca3330c85c052ac4f2e969e64ca7758fe558d2fc9f2c84ad2ebc4f869d4c",
                "image": "https://image.cnbcfm.com/api/v1/image/108318383-1780944003656-gettyimages-2279919808-AFP_B6EK9TC.jpeg?v=1780944021&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1782390956,
                "headline": "Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more"
              },
              {
                "id": 140723919,
                "url": "https://finnhub.io/api/news?id=a810afe55ccc6d991d4828e65543a28b9526212c51ef121db6a7d0e83b1a9458",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Shares of  Bio-Techne  surged before the opening bell on Thursday after Germany’s  Merck KGaA  announced it has agreed to purchase the company for $11.3 billion.  Bio-Techne stock jumped 21% to $70.95 in premarket trading on Thursday.  Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.",
                "category": "company",
                "datetime": 1782386280,
                "headline": "Germany’s Merck Is Buying Bio-Techne for $11.3 Billion"
              },
              {
                "id": 140729091,
                "url": "https://finnhub.io/api/news?id=e6863c9b865e6d27fdd72299cdce3221d0c00cfd208260a97a53c1500d7ef9c7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/25/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "FDA approves Gilead&#39;s Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.",
                "category": "company",
                "datetime": 1782386249,
                "headline": "Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer"
              },
              {
                "id": 140723920,
                "url": "https://finnhub.io/api/news?id=69d685115c1ba21a4dd0a640667438bb963b850e74e2a79d8fdd0507bbe4fda8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Germany’s Merck KGaA has announced a major acquisition agreement to buy U. S.",
                "category": "company",
                "datetime": 1782385056,
                "headline": "Germany’s Merck to Acquire Bio-Techne in $11.3 Billion Deal"
              },
              {
                "id": 140723921,
                "url": "https://finnhub.io/api/news?id=88e6dc07477e86c158a86650fd8f8b1f85cf071d8d7e26a7715ee71d886b9659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 25, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative br",
                "category": "company",
                "datetime": 1782384300,
                "headline": "FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)"
              },
              {
                "id": 140723922,
                "url": "https://finnhub.io/api/news?id=4c2ea899e14e67216e9444d62f90d53511b2c7824a476b3136cdedf1546d4a27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36%",
                "category": "company",
                "datetime": 1782382200,
                "headline": "Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets"
              },
              {
                "id": 140724629,
                "url": "https://finnhub.io/api/news?id=242b474ec3540cb65ce22afb0d9e3063b0e235fb9bfea18c6dbe0a8f1f0c4462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.",
                "category": "company",
                "datetime": 1782382080,
                "headline": "Germany’s Merck to Buy Bio-Techne for $11 Billion"
              },
              {
                "id": 140724395,
                "url": "https://finnhub.io/api/news?id=4103ee9f0605d35d70f4749bf7d87232b08923f7eebce92623e47d35efaab78e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1146642361/image_1146642361.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "GSK stock outlook: 3.46% dividend yield, 2026 core EPS growth guided at 7%–9%, and Exdensur as a new asthma growth driver—read the analysis now.",
                "category": "company",
                "datetime": 1782380178,
                "headline": "Is GSK Quietly Becoming An Oncology Powerhouse"
              },
              {
                "id": 140729092,
                "url": "https://finnhub.io/api/news?id=f72373c2d773fedf4214119cbb683f48a34a1d32c25101ff61937fa9cd30ac7c",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s",
                "category": "company",
                "datetime": 1782370449,
                "headline": "Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer"
              },
              {
                "id": 140721998,
                "url": "https://finnhub.io/api/news?id=1bb1ba6a3d41e7dd288a8668e75ab383ebe6cd18b53636aeb910f35a725a4618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 24, CICC initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating. It also set a $138 price target on the stock. Merck also provided an updated outlook during its first-quarter 2026 earnings call. […]",
                "category": "company",
                "datetime": 1782360518,
                "headline": "Merck (MRK) Stock Gets New Outperform Rating from CICC"
              },
              {
                "id": 140720797,
                "url": "https://finnhub.io/api/news?id=01dcfc8bf1f4b5374b14db8fd69d8059083f76ef475afca19bdb76d377095ff4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1449224970/image_1449224970.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "TCW Relative Value Large Cap Fund reports Q1 2026 performance and portfolio adjustments. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1782338700,
                "headline": "TCW Relative Value Large Cap Fund Q1 2026 Buys And Sells"
              },
              {
                "id": 140717005,
                "url": "https://finnhub.io/api/news?id=3f59a4c983b77042aa9b5c7b418ca5680832404b8328b939e755f4f4f4ef0e61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.",
                "category": "company",
                "datetime": 1782329550,
                "headline": "The Number That Could Test AbbVie Stock"
              },
              {
                "id": 140717060,
                "url": "https://finnhub.io/api/news?id=cf21eca9e56a27152b8fdb4d406b3ea9702f039e8f48562f3f9c7d336228c57f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global pharmaceutical leader MSD (Merck & Co., Inc., Rahway, New Jersey, USA) to explore the feasibility of establishing a logistics hub in Abu Dhabi's Health, Endurance, Longevity, and Medicine (HELM) Cluster.",
                "category": "company",
                "datetime": 1782328500,
                "headline": "Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region"
              },
              {
                "id": 140716596,
                "url": "https://finnhub.io/api/news?id=913f41419cf207e070247f93f2e5c79a4c26c31d243a3316ddb8b0588887e264",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1782328203,
                "headline": "Wednesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140715774,
                "url": "https://finnhub.io/api/news?id=b07b02658f5a1f627052bfdb8759128764dafe5a59adefdee020787600cd0033",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Density Gradient Media Market size & share revenue was valued at approximately USD 1.8 Billion in 2025 and is expected to reach USD 2 Billion in 2026 and is expected to reach around USD 5.3 Billion by 2035, at a CAGR of 11.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are GE Healthcare, Avantor Inc., ST",
                "category": "company",
                "datetime": 1782318600,
                "headline": "[Latest] Global Density Gradient Media Market Size/Share Worth USD 5.3 Billion by 2035 at a 11.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140715775,
                "url": "https://finnhub.io/api/news?id=131da7ac3242697939938400e8f3940e8625d88d13ca92411370d6ffe94c43c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.",
                "category": "company",
                "datetime": 1782314700,
                "headline": "Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC"
              },
              {
                "id": 140716350,
                "url": "https://finnhub.io/api/news?id=e91ff26077647b880e9d4dc41410cfc51f6b69b1332551a5ea8c2874d885cbb4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2281769390/image_2281769390.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "MacroGenics, Inc. downgraded to Hold after B7-H3 ADC setbacks; assess MGC026 phase 1 catalysts, pipeline risks, and liquidity outlook—click for this MGNX update.",
                "category": "company",
                "datetime": 1782311719,
                "headline": "MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment"
              },
              {
                "id": 140712894,
                "url": "https://finnhub.io/api/news?id=dff7ed81f12349a3014c0f3871606dd9362851f7a566bded7bfdb846b6bc376a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list. TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its […]",
                "category": "company",
                "datetime": 1782307612,
                "headline": "Is Merck & Co., Inc. (MRK) Strengthening Its Vaccine Portfolio With New Capvaxive Approval?"
              },
              {
                "id": 140712895,
                "url": "https://finnhub.io/api/news?id=af7dd1698707345a87c9e7febb0f8a711fd45f922d4e4112936860d0382df7a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Soft",
                "category": "company",
                "datetime": 1782303312,
                "headline": "Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More"
              },
              {
                "id": 140712211,
                "url": "https://finnhub.io/api/news?id=9ccc165297edd2622175778ed2c20535a5698d0aadc4dd3ef569f70fda7036ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), is approved in the European Union (EU), as neoadjuvant treatment and then continued after radical cystectomy (RC) as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin",
                "category": "company",
                "datetime": 1782297900,
                "headline": "European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer"
              },
              {
                "id": 140713702,
                "url": "https://finnhub.io/api/news?id=6903272a95031a3d5908c8d7f528a7ac331d3b7e6670ac3158181b2268c24815",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in collaboration with Pfizer and Astellas. In the study, KEYTRUDA plus Padcev, as perioperative",
                "category": "company",
                "datetime": 1782283685,
                "headline": "The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy"
              },
              {
                "id": 140707021,
                "url": "https://finnhub.io/api/news?id=a7a3d34f7810f7671686594b7ea4a20fe6d754140bd2b6fd7e9af81ef6290fe4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In June 2026, Merck reported positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, alongside recent US FDA approvals expanding KEYTRUDA–WELIREG use in kidney cancer and CAPVAXIVE’s indication to higher-risk children and adolescents. Together, these updates highlight Merck’s push to broaden its portfolio beyond oncology by advancing late-stage immunology assets and deepening its vaccines and cancer franchises. We’ll now examine...",
                "category": "company",
                "datetime": 1782249397,
                "headline": "How New Immunology and Vaccine Milestones At Merck (MRK) Have Changed Its Investment Story"
              },
              {
                "id": 140706976,
                "url": "https://finnhub.io/api/news?id=40cea8fb275d861a3becf0bae0ceea497224f2f0a3b6e14fb3a81a0e9b67bd1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.",
                "category": "company",
                "datetime": 1782244632,
                "headline": "The $50B Plan Merck Stock Was Broadcasting"
              },
              {
                "id": 140705613,
                "url": "https://finnhub.io/api/news?id=dacb874b40001fae147568e753562394b2ecc01221640017e808e3754fad2459",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St",
                "category": "company",
                "datetime": 1782243964,
                "headline": "Sector Update: Healthcare Stocks Higher Late Afternoon"
              },
              {
                "id": 140705639,
                "url": "https://finnhub.io/api/news?id=5dd36676d50cb28bd7056839a36f94b9a6b54c22b0b1215ccd6902bcad54e620",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]",
                "category": "company",
                "datetime": 1782243905,
                "headline": "Redditors Think Tempus AI (TEM) Still Has 10X Potential"
              },
              {
                "id": 140705127,
                "url": "https://finnhub.io/api/news?id=1a7c9bf7f2ceaedc51096b4f3a818a5b731ceb4599400e53810bafd7cd9672fc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.",
                "category": "company",
                "datetime": 1782241802,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 140705640,
                "url": "https://finnhub.io/api/news?id=0a6352c273c67e6ccbdcd2d5f379f41b11f856473120992e47eb06a540d66eb5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.",
                "category": "company",
                "datetime": 1782239040,
                "headline": "EXEL Down on Colorectal Cancer Study Data on Zanzalintinib"
              },
              {
                "id": 140704308,
                "url": "https://finnhub.io/api/news?id=55b4e6d315e5163a4cefd9286875131ce7a1a2f6b4d0e11cf68c3a82a7a92293",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.",
                "category": "company",
                "datetime": 1782229440,
                "headline": "Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study"
              },
              {
                "id": 140702600,
                "url": "https://finnhub.io/api/news?id=921a44a81749b4ef06389737c07a72d28c2efcae097c4e44898d2ffd854a0bb0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.",
                "category": "company",
                "datetime": 1782221400,
                "headline": "Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC"
              },
              {
                "id": 140701463,
                "url": "https://finnhub.io/api/news?id=5ffde01b735041e405b0af509d73949b64902768dc154cb1e72c5aff1906f451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September. They also see additional 25-basis-point hikes in October and December. The energy shock from the war with Iran drove inflation higher, with the CPI rising in ... Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants",
                "category": "company",
                "datetime": 1782218405,
                "headline": "Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants"
              },
              {
                "id": 140701432,
                "url": "https://finnhub.io/api/news?id=18f1e4cfd0598feca125bcf022d603484177055aad67802d5c5e9c2b913ef1ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.",
                "category": "company",
                "datetime": 1782217249,
                "headline": "Should You Buy Or Sell AbbVie Stock At $230?"
              },
              {
                "id": 140701816,
                "url": "https://finnhub.io/api/news?id=83194a81f1bf06c29625ac3301c189dc186f3aa0c269e33936a365610b43e658",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164210757/image_164210757.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Moderna, Inc. analysis: VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contracts—the rating shifts to Sell. Click for an update.",
                "category": "company",
                "datetime": 1782210358,
                "headline": "Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade)"
              },
              {
                "id": 140694637,
                "url": "https://finnhub.io/api/news?id=57d93cfe5cb4cdcf39a7ecafd1f85f9097d04dd077f968719235687de54a069a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1782155403,
                "headline": "Which dow jones stocks are moving on Monday?"
              },
              {
                "id": 140703465,
                "url": "https://finnhub.io/api/news?id=9d1a64273a07775e89905d50055b88836524c649b7a023e20cea7536c5b0697a",
                "image": "https://image.cnbcfm.com/api/v1/image/108322607-1781626040978-Traders-Photo-20260616-KK-PRESS-008.jpg?v=1781626133&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "The S&P 500 was lower on Tuesday as a tech sell-off that began during the prior session picked up steam overnight.",
                "category": "company",
                "datetime": 1782151292,
                "headline": "S&P 500 falls on global chip rout with Nasdaq off more than 1%, led by Micron: Live updates"
              },
              {
                "id": 140703670,
                "url": "https://finnhub.io/api/news?id=d560447c2ed49c61ad7c1fe00ea6c5c7cc97a6f006ba02b0e0ccba6be20ee622",
                "image": "https://image.cnbcfm.com/api/v1/image/108325149-17821648851782164882-46710721790-1080pnbcnews.jpg?v=1782164884&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Angelica Peebles joins 'Fast Money' with news of Pfizer's lung cancer drug trials.",
                "category": "company",
                "datetime": 1782150834,
                "headline": "Pfizer experimental lung cancer drug did not show survival benefit"
              },
              {
                "id": 140693165,
                "url": "https://finnhub.io/api/news?id=b412080a76ff6855e3d7788e06c5987d8344a2fbee28608b8e81ba5c389478a4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1782146403,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 140692527,
                "url": "https://finnhub.io/api/news?id=52cff7ec1098ae14406a3080b9e86f2a3739519ce6c8c3378d3ce8cb40cc2eb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.",
                "category": "company",
                "datetime": 1782139584,
                "headline": "Merck Stock’s New Drugs Were Already Answering The Big Question"
              },
              {
                "id": 140692529,
                "url": "https://finnhub.io/api/news?id=eeb880e0e03e6642499b51bf973887d5bc7190d2f207cc6898bd9360e56c032b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.",
                "category": "company",
                "datetime": 1782136320,
                "headline": "AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?"
              },
              {
                "id": 140703189,
                "url": "https://finnhub.io/api/news?id=47db52798bef3de379e79e247ea95edec3623ff1835042f0809c5f62d62865ee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/22/Woman-Touching-Stomach-Painful-Suffering.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.",
                "category": "company",
                "datetime": 1782134145,
                "headline": "Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy"
              },
              {
                "id": 140691615,
                "url": "https://finnhub.io/api/news?id=b27689a443afba49df3a51b1c4bbefef824c49b26741090cbc9f423edd0431ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel. The first line up of senior level clinical operation executives include: Jennifer Sheller, SVP, Head of Global Clinical Trial Operations, Global Clinical Development",
                "category": "company",
                "datetime": 1782129600,
                "headline": "Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference"
              },
              {
                "id": 140692530,
                "url": "https://finnhub.io/api/news?id=f9a239d45b4f5642301fd54de51f637dea58af907036b60b86743b112e5b01ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.",
                "category": "company",
                "datetime": 1782126720,
                "headline": "Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends"
              },
              {
                "id": 140690857,
                "url": "https://finnhub.io/api/news?id=3e8a422a8a9bdc331fc392484847538459d162d7315a7c9687e16718a1ac3b90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...",
                "category": "company",
                "datetime": 1782126603,
                "headline": "Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial"
              },
              {
                "id": 140690858,
                "url": "https://finnhub.io/api/news?id=50024d85cd1ef5f441faad3365ff384d7c00c47046c8562a92580c8cd178eda6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Score (",
                "category": "company",
                "datetime": 1782125100,
                "headline": "Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)"
              },
              {
                "id": 140692034,
                "url": "https://finnhub.io/api/news?id=865b9570ea14d8c83c150476046c7f244b91a195d4c74e1f47be8543a04a927f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398800679/image_1398800679.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. stock outlook: FDA approves Keytruda combo for kidney cancer as sales rise. Click here for this MRK update.",
                "category": "company",
                "datetime": 1782124439,
                "headline": "Merck's Oncology Engine Is Still Accelerating"
              },
              {
                "id": 140693108,
                "url": "https://finnhub.io/api/news?id=c3dd4ce5a78b06dbb39c73d7c540911d413f51e1d939e5e78e68cbabfb0744e9",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an",
                "category": "company",
                "datetime": 1782115556,
                "headline": "Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart"
              },
              {
                "id": 140689868,
                "url": "https://finnhub.io/api/news?id=cbdf5c1d9eac38e66e511197bec49ff667edd7e633abaf7853d2a609f2f19def",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) is one of Kevin O’Leary’s top stock picks for 2026 through the O’Shares U.S. Quality Dividend ETF. The stock made up 2.91% of the ETF as of June 17, 2026. On June 12, 2026, Merck said the US FDA approved KEYTRUDA and the easier-to-administer KEYTRUDA QLEX, each with WELIREG, for […]",
                "category": "company",
                "datetime": 1782114706,
                "headline": "Why Merck (MRK) Is Using KEYTRUDA and WELIREG to Deepen Its Kidney Cancer Franchise"
              },
              {
                "id": 140689869,
                "url": "https://finnhub.io/api/news?id=e4681ae47545cffe7e9e61c165afc401c0f9a428f0b391884fd88e17567e2d6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cheung Kong Graduate School of Business (CKGSB), a leading business school in China, hosted its 10th Economic Symposium at its new Beijing campus. The forum brought together ambassadors, policymakers, business leaders, and scholars to examine China's economic outlook and its evolving relationships with ASEAN and Europe amid geopolitical realignment, supply-chain restructuring and rapid technological change.",
                "category": "company",
                "datetime": 1782113040,
                "headline": "CKGSB Hosts 10th Economic Symposium in Beijing, Spotlighting China-ASEAN and China-Europe Economic Ties"
              },
              {
                "id": 140693109,
                "url": "https://finnhub.io/api/news?id=67ba39b5a4c3c3bc43e8f76785beaafefd6fca908c1928805c12a8670b637f3f",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an",
                "category": "company",
                "datetime": 1782111135,
                "headline": "Merk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission"
              },
              {
                "id": 140687069,
                "url": "https://finnhub.io/api/news?id=038182b20706846a8396b0e55102890345a59ae8195727fb4930bad0bb58f9f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026",
                "category": "company",
                "datetime": 1782073047,
                "headline": "The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026"
              },
              {
                "id": 140667013,
                "url": "https://finnhub.io/api/news?id=40038816fa54cd490942c62bfb04c763452a018b9dcd1c1764d125cf2b04ce44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.",
                "category": "company",
                "datetime": 1781830588,
                "headline": "How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story"
              },
              {
                "id": 140666631,
                "url": "https://finnhub.io/api/news?id=b65a89a175bc57a26cdb8820cd7ff4f3de192407b7468e0ead79b71a0fe37602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.",
                "category": "company",
                "datetime": 1781825349,
                "headline": "Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook"
              },
              {
                "id": 140666632,
                "url": "https://finnhub.io/api/news?id=83e04797ad5bfaba6e4ff56c17cd31a63b54a64d190a93f3295255d36fb03f03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.",
                "category": "company",
                "datetime": 1781819404,
                "headline": "Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know"
              },
              {
                "id": 140665981,
                "url": "https://finnhub.io/api/news?id=0b638c6ef191f5dbe4acd9d2334545c22003192c9ec27ab3ef212175c49ee56a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.",
                "category": "company",
                "datetime": 1781816249,
                "headline": "What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?"
              },
              {
                "id": 140671475,
                "url": "https://finnhub.io/api/news?id=04c7499d656cafdfb442d13e8677cc5baa001c9ba76b98009765eeed5ac4b408",
                "image": "https://image.cnbcfm.com/api/v1/image/108324290-17818192661781819251-46629128711-1080pnbcnews.jpg?v=1781819265&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.",
                "category": "company",
                "datetime": 1781805250,
                "headline": "Surge in biotech being driven by M&A, says UBS's Michael Yee"
              },
              {
                "id": 140663011,
                "url": "https://finnhub.io/api/news?id=4d9774503a2a14aa34d21a27219e2895f52ce0cfeed537f8ee7151f3a5776bb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "U.S. stocks rose in early Thursday trading, rebounding from the previous session’s Fed-driven selloff as falling oil prices and optimism surrounding the Iran peace deal boosted investor sentiment.",
                "category": "company",
                "datetime": 1781794324,
                "headline": "Dow Jumps 200 Points After Fed-Related Sell-Off – Index On Track To Post Best Week In A Month"
              },
              {
                "id": 140663082,
                "url": "https://finnhub.io/api/news?id=0d3c383fc254c63da01b9afeb83e08b2ed41a726c2714354ca3d4a7baf2ce06f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.",
                "category": "company",
                "datetime": 1781790660,
                "headline": "Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout"
              },
              {
                "id": 140663851,
                "url": "https://finnhub.io/api/news?id=e0b617c946abd34d90d997ad009d88dde012770474d780f7e43acc2b6aa1942d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227740127/image_2227740127.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SCHD faces near-term headwinds from rising interest rates and renewed investor preference for growth and AI-driven stocks. Read more on SCHD ETF here.",
                "category": "company",
                "datetime": 1781789870,
                "headline": "Dumping SCHD"
              },
              {
                "id": 140663130,
                "url": "https://finnhub.io/api/news?id=c17fe083e38c20a2c0c6b0c283b9582ea59c3d593694f70299817c6311a6de1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.",
                "category": "company",
                "datetime": 1781787420,
                "headline": "GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections"
              },
              {
                "id": 140661963,
                "url": "https://finnhub.io/api/news?id=c310ad8bce4ee2274e1f7174fc5fe1843735f12bb0df695be7b43742420deaba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "WATERTOWN, Mass., June 18, 2026--Today, Portal Biotechnologies, Inc. (\"Portal\"), a cell engineering and drug discovery platform company, announced updates on significant commercial progress and the closing of an oversubscribed $9M financing round led by NFX and participation from existing investors including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures.",
                "category": "company",
                "datetime": 1781782200,
                "headline": "Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers"
              },
              {
                "id": 140664292,
                "url": "https://finnhub.io/api/news?id=2c76d72ef28c16019c44065fa3981f584a4833b6c01bce3b7b27d649bc7883c8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/18/Merck.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.",
                "category": "company",
                "datetime": 1781782166,
                "headline": "FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens"
              },
              {
                "id": 140662049,
                "url": "https://finnhub.io/api/news?id=27d91870d4a135d0602b1451388146d57a45fdc296d0e32cde168d450acedc7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 18, 2026--U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine)",
                "category": "company",
                "datetime": 1781779500,
                "headline": "U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease"
              },
              {
                "id": 140664293,
                "url": "https://finnhub.io/api/news?id=5d3bf10394d1486e23cb9fcbb71004c75b95a82639ae356b78e0db2c84c70fb1",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Expansion to to include children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series and have one or more chronic medical conditions that put them at an",
                "category": "company",
                "datetime": 1781765332,
                "headline": "Merck Announces FDA Approval Of An Expanded Indication For Its Pneumococcal Vaccine CAPVAXIVE"
              },
              {
                "id": 140656229,
                "url": "https://finnhub.io/api/news?id=82a16893ba9d8633e1d9bbcaff0957620069ba8801c0cf187ee39b78f1b53105",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) announced a multi target AI drug discovery collaboration with Protillion Biosciences, focused on high throughput protein engineering for new therapeutics. The agreement includes potential milestone payments tied to progress across multiple discovery programs. Merck also launched a global HPV awareness initiative with Nivi, aimed at emerging markets with high cervical cancer burden. The Nivi partnership uses digital and AI powered health education tools to support HPV...",
                "category": "company",
                "datetime": 1781723460,
                "headline": "Merck (MRK) Taps Protillion For AI Drug Discovery And Expands HPV Outreach"
              },
              {
                "id": 140656174,
                "url": "https://finnhub.io/api/news?id=2aa3c28a6316d21cd0b3a250dbcd7a34faab4f462d8a0077eef69088034ae1a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.",
                "category": "company",
                "datetime": 1781720514,
                "headline": "Eli Lilly Stock's Trillion-Dollar Question"
              },
              {
                "id": 140654898,
                "url": "https://finnhub.io/api/news?id=585df5c1129db77351eae45d0cef4ca7a69eb6baa849d876f3552f29b8ba324a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for the adjuvant treatment of adult patients with renal cell carcinoma […]",
                "category": "company",
                "datetime": 1781717712,
                "headline": "Here’s Why Merck (MRK) is Among the 10 Undervalued Counter Cyclical Stocks to Buy Now"
              },
              {
                "id": 140654899,
                "url": "https://finnhub.io/api/news?id=faac09a7f7de9bb4173c55109249682bbd623df9bd8481309582c5dd8cd306af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]",
                "category": "company",
                "datetime": 1781717681,
                "headline": "Gilead Sciences (GILD) Donates Remdesivir to Uganda"
              },
              {
                "id": 140654900,
                "url": "https://finnhub.io/api/news?id=99429aba5ebe6b2b438534e251639e00fe2cf677b826153bbfc093a1d746ca94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa.",
                "category": "company",
                "datetime": 1781717376,
                "headline": "MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts"
              },
              {
                "id": 140654833,
                "url": "https://finnhub.io/api/news?id=0af54b09cc456b697d54b1cbe3268af507e3f7ce906b018927f8e52bf8c00d41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.",
                "category": "company",
                "datetime": 1781716091,
                "headline": "The Number That Could Test Johnson & Johnson Stock"
              },
              {
                "id": 140654836,
                "url": "https://finnhub.io/api/news?id=75650634439443a1b3278415e11c94f5fd9a43ed9188da817a87e5cdb95ed5fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.",
                "category": "company",
                "datetime": 1781711865,
                "headline": "Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished"
              },
              {
                "id": 140652606,
                "url": "https://finnhub.io/api/news?id=5f74783d0848e3e6bdcabd0c851a4f6d1268c1b9942cac442aad7b71999fb5db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Nectin Therapeutics, a clinical-stage oncology company developing first-in-class immuno-oncology and antibody-drug conjugate (ADC) therapies, today announced the presentation of Phase 1a/1b clinical data of NTX1088 in combination with pembrolizumab (Keytruda®), Merck's (known as MSD outside of the U.S. and Canada) anti-PD1 therapy, during an oral presentation at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.",
                "category": "company",
                "datetime": 1781697660,
                "headline": "Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026"
              },
              {
                "id": 140651825,
                "url": "https://finnhub.io/api/news?id=320ce554d0041e34633ddbc09c7d9333d0a85c76dc93b54ef80a6bd0e739e365",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., June 17, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-third of c",
                "category": "company",
                "datetime": 1781693100,
                "headline": "Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages"
              },
              {
                "id": 140652201,
                "url": "https://finnhub.io/api/news?id=a2ef39c34fb0bfe6bb16b51d79dbdde95bbae2a636d8d315c55dd1a6f957cc5d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232611876/image_2232611876.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Discover why SCHD is a core dividend ETF: 3.25% yield, 0.06% fee, tech/health tilt, and resilient income potential—see if it fits your portfolio.",
                "category": "company",
                "datetime": 1781686800,
                "headline": "SCHD: Not My Highest Yielder, But It May Be My Most Important ETF"
              },
              {
                "id": 140651281,
                "url": "https://finnhub.io/api/news?id=ca6315fb1976875f2c3a05c2f6e021b21a0606468c3a448f64d984ce6fe5581a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.",
                "category": "company",
                "datetime": 1781682060,
                "headline": "The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK"
              },
              {
                "id": 140650764,
                "url": "https://finnhub.io/api/news?id=8f3bcd29573c555edc837b4e88b4bd453f6fd84da2fee3698df33c9d5aebf7f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SpaceX’s  $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance.  It’s not the first time an IPO has shaken things up.  IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.",
                "category": "company",
                "datetime": 1781679600,
                "headline": "How America Got to SpaceX: The Long Trail of Big IPOs That Began in 1783"
              },
              {
                "id": 140649580,
                "url": "https://finnhub.io/api/news?id=ae7b668d55440a253dac0b3035c32afc96bb0c1d934f668e5e287108357a66dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lill",
                "category": "company",
                "datetime": 1781649000,
                "headline": "[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140647921,
                "url": "https://finnhub.io/api/news?id=f9bf47629703209c3e1af6602e954402634d8842d39c9c3ecbbe94a804281c9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.",
                "category": "company",
                "datetime": 1781633820,
                "headline": "FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention"
              },
              {
                "id": 140645608,
                "url": "https://finnhub.io/api/news?id=2da5bbdc6b5f0d0ba16175d692487797ffd5db915d47f5cdb241238f47dcac1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audience, today announced it has established an investment interest in Rejuvenate Bio.",
                "category": "company",
                "datetime": 1781622060,
                "headline": "Jetstream Venture Fund Secures Position in Rejuvenate Bio, Investing Alongside Industry Giant Merck"
              },
              {
                "id": 140645550,
                "url": "https://finnhub.io/api/news?id=322a611983811780d1211ebed8398e35452120dbde1210c1c2dd3473ad32c938",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.",
                "category": "company",
                "datetime": 1781618820,
                "headline": "AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?"
              },
              {
                "id": 140644937,
                "url": "https://finnhub.io/api/news?id=aa729e29ac7c3bacb6f2e76ba7b497b4471ffc49e0f8cc52ae270d8623c3b67a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Nivi, Inc., a digital health innovator specializing in personalized healthcare guidance and consumer insights, and MSD (known as Merck Sharp & Dohme LLC in the United States and Canada, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA) today announced a global initiative to enhance consumer awareness of HPV diseases and HPV-related cervical cancer prevention across emerging markets, beginning with India, Indonesia, and Thailand.",
                "category": "company",
                "datetime": 1781611320,
                "headline": "Nivi, Inc. and MSD Collaborate to Expand HPV Disease Awareness and Cervical Cancer Prevention Through AI-Powered Platform"
              },
              {
                "id": 140644938,
                "url": "https://finnhub.io/api/news?id=c6bc96f5d1286e942590a9060e09aceb90b50b2ac6f0318737dbe676d60623e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "CARLSBAD, Calif., June 16, 2026--Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The agreement combines Protillion’s proprietary platform with Merck’s global expertise in the discovery of novel therapeutic candidates.",
                "category": "company",
                "datetime": 1781611200,
                "headline": "Protillion Biosciences Announces Drug Discovery Collaboration with Merck"
              },
              {
                "id": 140644488,
                "url": "https://finnhub.io/api/news?id=f23c319fa05e6e90ad92ce0662ca0c2f3d47ba16d62c574b68acfdb35fbd2640",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "They have a habit of consistently raising their payouts.",
                "category": "company",
                "datetime": 1781606100,
                "headline": "3 Dividend Stocks to Hold for the Long Haul"
              },
              {
                "id": 140648478,
                "url": "https://finnhub.io/api/news?id=6eec3e4da30393d0e89696fa224b64ea2da1170e4e759cce1e9e71b4e1d6c6b3",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and",
                "category": "company",
                "datetime": 1781597796,
                "headline": "Protillion Biosciences Signs Discovery Collaboration, License Deal With Merck To Integrate Its Platform With Merck's Expertise For Novel Therapeutic Candidates Discovery"
              },
              {
                "id": 140644385,
                "url": "https://finnhub.io/api/news?id=a2a495cffebf14c7955057066de6309690077e686f804b6e94080bc5df3a8dfa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2213351007/image_2213351007.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck looks like a buy-the-dip at $114.90 with a 3% yield and 12x forward P/E. Click here to read more on the MRK stock.",
                "category": "company",
                "datetime": 1781594108,
                "headline": "Merck: Buy The Dip On This Dividend Growth Pharma Leader"
              },
              {
                "id": 140639467,
                "url": "https://finnhub.io/api/news?id=45d96341a355eed5c643fc24508153b0829c1da5af3f88702651d3714f07b3ec",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1781550603,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 140638896,
                "url": "https://finnhub.io/api/news?id=54cebd268783a5d88980e6b1060c5d8694770c1473fe189ec6de93e2541f8544",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.",
                "category": "company",
                "datetime": 1781545147,
                "headline": "3 Stocks Estimated To Be Up To 46.2% Below Fair Value Offering A 12.2% Discount Opportunity"
              },
              {
                "id": 140636737,
                "url": "https://finnhub.io/api/news?id=62287e5fcdfa070b0f1a08c2fd9d9236f9f1d3ced83a1999d83ae3f16f73d20c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.",
                "category": "company",
                "datetime": 1781523522,
                "headline": "June 2026's Noteworthy Stocks Estimated Below Intrinsic Value"
              },
              {
                "id": 140636746,
                "url": "https://finnhub.io/api/news?id=5d8234b6086f8cebb6c9cafc567c20fe7dbd806bf07d14641e27ab0295510335",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Offic",
                "category": "company",
                "datetime": 1781523000,
                "headline": "Immuneering Appoints Andrew Gengos as Chief Financial Officer"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": -0.3,
            "source_article_count": 234,
            "discarded_article_count": 207
          },
          "sentimentPoints": 1
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 11648883.333333334,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8818900,
              "avg_vol_20": 11478120,
              "avg_vol_30": 11648883.333333334,
              "range_pct_10": 0.0649941215433018,
              "range_pct_20": 0.1549924656400066,
              "range_pct_30": 0.1549924656400066,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7570596895553651,
              "dist_to_20d_high": 0.07299094888256565,
              "down_shrink_days": 5,
              "breakout_level_20d": 130.28999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4193372966545384
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.9244080145719487,
              "turnoverUsdM": 1096.94002374,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRK",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 113.7158,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.8,
            "take_profit_price": 127.8265,
            "target_multiplier": 1.9,
            "technical_strength": 1.58,
            "take_profit_percent": 5.8
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.848816029143897,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.MRK",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.5321,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.92
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -17.66
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.161
    },
    "kdj": {
      "d": 41.56,
      "j": -12.49,
      "k": 23.54,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 50.59
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 665367,
      "recentSlope": -2938473.3,
      "previousSlope": 5375500
    },
    "rsi": 51.85,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 130.29,
      "position": "SAR喺價上",
      "distancePct": 7.87,
      "previousTrend": "上升"
    },
    "ma50": 118.7166,
    "macd": {
      "macd": 1.651129575951785,
      "trend": "中性偏多",
      "signal": 2.2814601601450333,
      "histogram": -0.6303305841932483
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 121.8555,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.8,
      "score": 2,
      "avgVolume": 11385882,
      "currentVolume": 9082133
    },
    "derived": {
      "ma20": 122.8515,
      "ma50": 118.7166,
      "prevClose": 124.03,
      "avgVolume10": 8768653,
      "avgVolume20": 11385882,
      "changePercent": -2.62,
      "avgVolumeForScore": 11385882
    },
    "ma_cross": {
      "ma20": 122.8515,
      "ma50": 118.7166,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 122.765,
      "prevMa50": 118.4846,
      "spreadPct": 3.48,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 112.206,
      "upper": 133.497,
      "position": "中間"
    },
    "rsi_short": 23.07,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.8
    }
  }
}

{
  "close": 120.78,
  "volume": 9082133,
  "changePercent": -2.62
}